Inovio Pharmaceuticals Inc (INO)

[Lakers_w]

If by June 30, 2022, MGMT Methylated Median (cohort B) OS36 = OS30 = OS24 (95% CI) = 55%, n Alive/N Total = 11/20, Ino will extend the trial for another 6 month, could apply for Orphan Designation, qualify for Compassionate Use, and maybe lobby Biden for EUA in memory of Beau, aka Beau vaccine/treatment.

• Inovio’s INO-5401 is a DNA medicine composed of plasmids that encode for the tumor associated antigens human telomerase (hTERT), Wilms tumor-1 (WT-1), and prostate-specific membrane antigen (PSMA); INO-9012 is a synthetic DNA plasmid that encodes for human IL-12 designed to stimulate T cells locally without a systemic effect
• Cemiplimab is a high-affinity, highly potent, human, hinge-stabilized IgG4 monoclonal antibody to the PD-1 receptor
• Create an antigen-specific, activated T cell population
• Inovio has shown that INO-5401+INO-9012 with cemiplimab and 40 Gy radiation/TMZ have an acceptable safety profile and are immunogenic